ERBB2 and triple-negative breast carcinoma: Immunohistochemistry assessment of receptors status evidenced that 47,62% (10/33) were HER2-positive, 85,71% (19/33) were HER2-negative and only 23,81% (5/33) were triple negative breast cancer (TNBC) (Fig. 2).